These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38834951)

  • 21. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
    Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
    Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary cervical screening with high risk human papillomavirus testing: observational study.
    Rebolj M; Rimmer J; Denton K; Tidy J; Mathews C; Ellis K; Smith J; Evans C; Giles T; Frew V; Tyler X; Sargent A; Parker J; Holbrook M; Hunt K; Tidbury P; Levine T; Smith D; Patnick J; Stubbs R; Moss S; Kitchener H
    BMJ; 2019 Feb; 364():l240. PubMed ID: 30728133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
    Agorastos T; Chatzistamatiou K; Moysiadis T; Kaufmann AM; Skenderi A; Lekka I; Koch I; Soutschek E; Boecher O; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Boschetti Gruetzmacher E; Tsertanidou A; Angelis L; Maglaveras N; Jansen-Duerr P
    Int J Cancer; 2017 Aug; 141(3):519-530. PubMed ID: 28470689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The meaning of high-risk HPV other than type 16/18 in women with negative cytology: Is it really safe to wait for 1 year?
    Kabaca C; Giray B; Guray Uzun M; Akis S; Purut YE; Keles Peker E; Cetiner H; Bostanci Ergen E
    Diagn Cytopathol; 2021 Apr; 49(4):480-486. PubMed ID: 33528903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical performance of human papillomavirus based cervical cancer screening algorithm: The result of a large Danish implementation study.
    Lindquist S; Kjær SK; Frederiksen K; Ørnskov D; Petersen LK; Munk C; Waldstrøm M
    Acta Obstet Gynecol Scand; 2024 Sep; 103(9):1781-1788. PubMed ID: 39012789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human papilloma virus genotype distribution in women with premalignant or malignant lesions of the uterine cervix.
    Stuebs FA; Gass P; Dietl AK; Schulmeyer CE; Adler W; Geppert C; Hartmann A; Knöll A; Beckmann MW; Koch MC
    Arch Gynecol Obstet; 2021 Sep; 304(3):751-758. PubMed ID: 33538863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Performance of human papillomavirus typing test in cervical precancer lesions and cervical cancer screening].
    Zhang SK; Luo XP; Li ZF; Su Z; Xia JC; Hu GY; Zhu YJ; Xie LX; Feng XX; Sun XB; Chen W; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):252-256. PubMed ID: 32252206
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost and effectiveness comparison of immediate colposcopy versus human papillomavirus DNA testing in management of atypical squamous cells of undetermined significance in Turkish women.
    Kececioglu M; Seckin B; Baser E; Togrul C; Kececioglu TS; Cicek MN; Gungor T
    Asian Pac J Cancer Prev; 2013; 14(1):511-4. PubMed ID: 23534785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of high risk HPV genotype on colposcopic performance: A large prospective study demonstrates improved detection of disease with ZedScan I, particularly in non-HPV 16 patients.
    Macdonald MC; Brown BH; Lyon RE; Healey TJ; Palmer JE; Tidy JA
    Eur J Obstet Gynecol Reprod Biol; 2017 Apr; 211():194-198. PubMed ID: 28292693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer.
    Barrett JE; Sundström K; Jones A; Evans I; Wang J; Herzog C; Dillner J; Widschwendter M
    Genome Med; 2022 Oct; 14(1):116. PubMed ID: 36258199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human Papilloma Virus Typing as a Triage Tool for Women with Postcoital Bleeding: A Retrospective Cohort Study.
    Akdam A; Van Mil L; Tzur Y; Laskov I; Grisaru D; Schejter E; Michaan N
    J Womens Health (Larchmt); 2024 Jun; 33(6):734-740. PubMed ID: 38502831
    [No Abstract]   [Full Text] [Related]  

  • 35. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
    Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
    BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results.
    Bandyopadhyay S; Austin RM; Dabbs D; Zhao C
    Arch Pathol Lab Med; 2008 Dec; 132(12):1874-81. PubMed ID: 19061283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
    Song F; Du H; Wang C; Huang X; Wu R;
    PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [To analyse the histopathological results of patients with HPV16/18 positive and colposcopic suspicious lesions].
    Zhang JX; Zheng TP; Liu J; Wang QX; Zhan YX; Zhang ZY
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jul; 52(7):467-472. PubMed ID: 28797154
    [No Abstract]   [Full Text] [Related]  

  • 39. High-risk HPV testing vs liquid-based cytology for cervical cancer screening among 25- to 30-year-old women: A historical cohort study.
    Feldstein O; Gali-Zamir H; Schejter E; Feinberg T; Yehuda-Shnaidman E; Bornstein J; Levy T
    Acta Obstet Gynecol Scand; 2023 Feb; 102(2):226-233. PubMed ID: 36478537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.